EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline DataGlobeNewsWire • 05/14/26
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 05/06/26
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share InvestmentThe Motley Fool • 03/15/26
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/04/26
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 03/02/26
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026GlobeNewsWire • 02/25/26
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?Zacks Investment Research • 02/18/26
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26